-
Start Preamble
Pursuant to 21 CFR 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 9, 2004, Lin Zhi International Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed in Schedule II.
Drug Schedule Oxycodone (9143) II Hydrocodone (9193) II The company plans to manufacture the listed controlled substances in bulk for use in analysis and drug test standards.
Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a)
Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than May 3, 2005.
Start SignatureDated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 05-4222 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 03/04/2005
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- 05-4222
- Pages:
- 10680-10680 (1 pages)
- PDF File:
- 05-4222.pdf